Skip to main
MGNX
MGNX logo

MacroGenics (MGNX) Stock Forecast & Price Target

MacroGenics (MGNX) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 40%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Macrogenics Inc. has demonstrated significant capability in antibody engineering and has developed a robust pipeline of promising product candidates, including its lead product MARGENZA for metastatic HER2-positive breast cancer. The company's strategic collaborations with global pharmaceutical and biotechnology firms enhance its market position and potential for future revenue generation, indicating a strong trajectory in the competitive biopharmaceutical landscape. Additionally, the anticipated increase in data flow from early-stage programs, coupled with the recent initiation of patient dosing in pivotal trials, suggests opportunities for non-dilutive capital through strategic partnerships, contributing to a positive outlook for the company's financial performance.

Bears say

Macrogenics Inc reported lower-than-expected revenue of $13 million, coupled with a significant GAAP net loss of $41 million, or $(0.65) per share, which exceeded initial and consensus estimates. The company's research and development expenditure amounted to $40 million, reflecting a 23% year-over-year decline, indicating potential challenges in its developmental pipeline. Additionally, the total operating expenses decreased by 19% year-over-year at $56 million, further highlighting concerns regarding the company’s financial health and operational efficiency amidst ongoing losses.

MacroGenics (MGNX) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 40% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MacroGenics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MacroGenics (MGNX) Forecast

Analysts have given MacroGenics (MGNX) a Hold based on their latest research and market trends.

According to 5 analysts, MacroGenics (MGNX) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MacroGenics (MGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.